Stock Events

Stock Events

Clinuvel Pharmaceuticals 

$4.95
102
+$0.00+0%Friday 19:58

Statistics

Day High
5.04
Day Low
4.95
52W High
8.45
52W Low
4.95
Volume
300
Avg. Volume
1,120
Mkt Cap
249.91M
P/E Ratio
13.86
Dividend Yield
0.68%
Dividend
0.03

Upcoming

Dividends

0.68%Dividend Yield
Sep 2026
$0.04
Sep 2025
$0.03
Sep 2024
$0.03
Sep 2023
$0.03
Sep 2022
$0.03
10Y Growth
N/A
5Y Growth
14.87%
3Y Growth
N/A
1Y Growth
N/A

Earnings

Feb 23Expected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
Next
0.19
0.29
0.39
0.49
Expected EPS
0.25224615211454715
Actual EPS
N/A

Financials

-9.98%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.97BRevenue
-495.64MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLVLF. It's not an investment recommendation.
Coca-Cola
9
CCC3.F
Microsoft
8
MSF.F
Microsoft
8
MSFT
Alphabet
8
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Icon
ICLR
Mkt Cap15.34B
ICON plc provides clinical research services to the pharmaceutical, biotechnology, and medical device industries, competing in the development and commercialization of dermatological treatments similar to Clinuvel's focus.
Pfizer
PFE
Mkt Cap167.52B
Pfizer Inc. is involved in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products, including treatments in areas that overlap with Clinuvel's therapeutic focus.
Merck
MRK
Mkt Cap361.73B
Merck & Co., Inc. offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing in areas such as skin conditions and rare diseases.
Novartis
NVS
Mkt Cap307B
Novartis AG researches, develops, manufactures, and markets healthcare products in areas that compete with Clinuvel, including dermatology and rare diseases.
GSK
GSK
Mkt Cap100.88B
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, including skin health products that compete with Clinuvel's portfolio.
Johnson & Johnson
JNJ
Mkt Cap664.95B
Johnson & Johnson researches and develops, manufactures, and sells a broad range of products in the healthcare field, including competitive offerings in dermatology and rare diseases.
Abbvie
ABBV
Mkt Cap514.92B
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products directly competing in the dermatology and rare disease market segments targeted by Clinuvel.
AMGEN
AMGN
Mkt Cap249.05B
Amgen Inc. focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise, competing in the development of treatments for conditions that Clinuvel also targets.
Regeneron Pharmaceuticals
REGN
Mkt Cap93.55B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including skin diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.85B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic diseases that overlap with Clinuvel's focus areas.

About

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
Show More
CEO
Philippe Jacques Wolgen
Employees
100
Country
Australia
ISIN
AU000000CUV3
WKN
000A0JEGY

Listings

F
DE
UR9.F
XNAS
US
CUVL
MU
DE
UR9A.MU
STU
DE
UR9A.STU

0 Comments

Share your thoughts

FAQs

What is Clinuvel Pharmaceuticals stock price today?▼
The current price of CLVLF is $4.95 USD — it has increased by +0% in the past 24 hours. Watch Clinuvel Pharmaceuticals stock price performance more closely on the chart.
What is Clinuvel Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Clinuvel Pharmaceuticals stocks are traded under the ticker CLVLF.
Is Clinuvel Pharmaceuticals stock price growing?▼
CLVLF stock has risen by +0% compared to the previous week, the month change is a -7.99% fall, over the last year Clinuvel Pharmaceuticals has showed a -34.52% decrease.
What is Clinuvel Pharmaceuticals market cap?▼
Today Clinuvel Pharmaceuticals has the market capitalization of 249.91M
When is the next Clinuvel Pharmaceuticals earnings date?▼
Clinuvel Pharmaceuticals is going to release the next earnings report on February 23, 2027.
What were Clinuvel Pharmaceuticals earnings last quarter?▼
CLVLF earnings for the last quarter are 0.33 USD per share, whereas the estimation was 0.35 USD resulting in a -6.13% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Clinuvel Pharmaceuticals revenue for the last year?▼
Clinuvel Pharmaceuticals revenue for the last year amounts to 4.97B USD.
What is Clinuvel Pharmaceuticals net income for the last year?▼
CLVLF net income for the last year is -495.64M USD.
Does Clinuvel Pharmaceuticals pay dividends?▼
Yes, CLVLF dividends are paid annual. The last dividend per share was 0.04 . As of today, Dividend Yield (FWD)% is 0.68%.
How many employees does Clinuvel Pharmaceuticals have?▼
As of November 15, 2026, the company has 100 employees.
In which sector is Clinuvel Pharmaceuticals located?▼
Clinuvel Pharmaceuticals operates in the Health & Wellness sector.
When did Clinuvel Pharmaceuticals complete a stock split?▼
The last stock split for Clinuvel Pharmaceuticals was on November 12, 2010 with a ratio of 1:10.
Where is Clinuvel Pharmaceuticals headquartered?▼
Clinuvel Pharmaceuticals is headquartered in Melbourne, Australia.